Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 11/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL753807 | 1.00 | HSD11B1 (0.53) | HSD11B1LMNAGAAMEN1KMT2A | |
| SCHEMBL752568 | 0.82 | ACHE (0.52) | HSD11B1LMNAGAAMEN1KMT2A | |
| SCHEMBL733606 | 0.81 | HSD11B1 (0.64) | HSD11B1LMNAGAAMEN1KMT2A | |
| SCHEMBL13789607 | 0.78 | KMT2A (0.60) | HSD11B1LMNAGAAMEN1KMT2A | |
| SCHEMBL751891 | 0.76 | ALDH1A1 (0.51) | HSD11B1LMNAGAAMEN1KMT2A | |
| SCHEMBL762993 | 0.76 | ALDH1A1 (0.51) | HSD11B1LMNAGAAMEN1KMT2A | |
| SCHEMBL751898 | 0.75 | HSD11B1 (0.53) | HSD11B1LMNAGAAMEN1KMT2A | |
| SCHEMBL763799 | 0.75 | HSD11B1 (0.53) | HSD11B1LMNAGAAMEN1KMT2A | |
| SCHEMBL734562 | 0.73 | HSD11B1 (0.58) | HSD11B1LMNAGAAMEN1KMT2A | |
| SCHEMBL10152899 | 0.71 | PKM (0.50) | HSD11B1LMNAGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170234881-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-08-17 | — | — | US | disclosed |
| US-8138190-B2 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090176768-A1 | DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES | AMGEN INC. | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176768-A1 | DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES | GPR119, GLP1R, INSR | HSD11B1 2477/4885LMNA 2505/4885GAA 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.